Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females

NCT ID: NCT00568126

Last Updated: 2020-08-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-12-27
• Study Completion Date: 2010-10-05

Brief Summary

The purpose of this study is to find out whether Maca Root is effective for treating sexual dysfunction in females that is caused by antidepressant drugs. An additional aim of the study is to document the safety and tolerability of maca root, as well as any potential side effects that it causes.

Detailed Description

This is a 12-week, double-blind, placebo-controlled trial comparing maca root (3.0 g/day) versus an inactive placebo in female outpatients with SSRI/SNRI-induced sexual dysfunction whose depression had remitted with SSRI treatment. Outcome measures include improvement in sexual functioning as per the Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ).

Conditions

Antidepressant Induced Sexual Dysfunction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Maca Root

Subjects in this arm will be given 3g/day of maca root for 12 weeks

Group Type: EXPERIMENTAL

Maca Root

Intervention Type: DRUG

3g/day of Maca Root for 12 weeks.

Placebo

Subjects in this arm will receive inactive placebo for 12 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo provided by research pharmacy daily for 12 weeks.

Interventions

Maca Root

3g/day of Maca Root for 12 weeks.

Intervention Type: DRUG

Placebo

Placebo provided by research pharmacy daily for 12 weeks.

Intervention Type: DRUG

Other Intervention Names

Lepidium; Inactive placebo

Eligibility Criteria

Inclusion Criteria

• Subject is female, age 18 to 80 years
• Subject has been taking an SSRI, venlafaxine, or tri/heterocyclic antidepressant for the treatment of depression for at least 8 weeks; and is currently on a stable dose of the antidepressant for at least 4 weeks
• Subject is currently euthymic (HAM-D < 10) and is without significant anxiety symptoms (HAM-A < 10)
• Subject must have had no sexual dysfunction prior to taking antidepressant and there must be a clear temporal relationship between the sexual dysfunction and the antidepressant treatment
• Subject must have been consistently experiencing at least one of the following criteria for at least 4 weeks, with distress or disability:

• Inability to have an orgasm, according to patient opinion
• Clinically significant orgasm delay with masturbation or intercourse
• Inability to attain or maintain until completion of sexual activity an adequate lubrication swelling response of sexual excitement
• Decreased libido according to patient opinion
• Subject must be having or had been having some form of regular sexual activity (masturbation, oral sex, intercourse) at least twice monthly prior to the antidepressant treatment and are willing to continue efforts at sexual activity at least once weekly for the duration of the study
• Subject must be in good general physical health
• Subject must be able to understand and communicate in English
• Subject must have given informed consent to participate in the study

Exclusion Criteria

• Primary or prior diagnosis of a sexual disorder (other than the side effect of the bipolar medication or symptom of the bipolar disorder)
• Sexual dysfunction secondary to general underlying medical condition
• Penile, vaginal, clitoral or other sexual organ anatomical deformities
• Any uncontrolled psychiatric disorder
• Alcohol or substance abuse or dependence within the past six months
• Recent major relationship changes, disruption, or turmoil ongoing or anticipated which are unrelated to her sexual dysfunction
• Hamilton Depression and/or Anxiety Scale score (either) > 10
• Blood pressure outside the range of 90/50 - 170/100
• Known hyperprolactinemia
• Use of investigational drugs within previous 3 months or during study
• Current use of other drugs for antidepressant induced sexual dysfunction or other therapies or medications to treat sexual dysfunction
• Current use of nefazodone
• Hormone replacement therapy, unless patient has been on stable dose of hormone therapy for at least 3 mo prior to the antidepressant treatment and had no sexual dysfunction while on the same hormone therapy regimen, and there is no change in the HRT during the study
• Pregnancy, lactating, or planning to become pregnant during the study
• Child bearing potential subjects unwilling and/or not prepared and/or who are judged unreliable to use an acceptable and verifiable form of contraception during the study
• Any clinically significant abnormality on the screening physical examination
• History of hormonal cancers
• Any medical or psychological condition or social circumstances that would impair subject's ability to participate reliably in the study, or that may increase the risk to subjects or others as a result of participating in this study
• Dyspareunia secondary to an inflammatory or anatomical condition
• Prior use of maca for at least two weeks
• Infection of the urogenital tract that may make sexual activity painful or difficult
• Subjects whose sexual partners are suffering from and/or receiving treatment for sexual dysfunction
• Receiving psychosexual or other therapy for sexual dysfunction and not willing to discontinue that treatment at screening
• Subjects who do not understand and communicate in English
• Subjects for whom sexual activity is inadvisable
• Subjects whose sexual dysfunction is considered to be situational
• Subjects not attempting some form of regular sexual activity at least twice monthly and at least once weekly during study visit intervals for duration of entire study
• Changes in antidepressant agent and/or dose of medication within the last 4 weeks before baseline visit
• Participants on medications with a narrow therapeutic window or low therapeutic index for which small variations may be harmful given the lack of systematic experience with drug-supplement interactions (i.e. - cyclosporine, digoxin, warfarin, and antiretrovirals)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

Sponsor Role: collaborator

A Healthy Alternative, LLC

OTHER

Sponsor Role: collaborator

Massachusetts General Hospital

OTHER

Sponsor Role: lead

Responsible Party

David Mischoulon, MD, PhD

Physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Christina Dording, MD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

David Mischoulon, MD, PhD

Role: STUDY_DIRECTOR

Massachusetts General Hospital

Locations

Depression Clinical and Research Program, Massachusetts General Hospital

Boston, Massachusetts, United States

Countries

United States

References

Dording CM, Schettler PJ, Dalton ED, Parkin SR, Walker RS, Fehling KB, Fava M, Mischoulon D. A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women. Evid Based Complement Alternat Med. 2015;2015:949036. doi: 10.1155/2015/949036. Epub 2015 Apr 14.

Reference Type: RESULT

PMID: 25954318 (View on PubMed)

Other Identifiers

R21AT004385

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2007P001090

Identifier Type: -

Identifier Source: org_study_id